Mesenchymal Stem Cell Infusion for COVID-19 Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04444271|
Recruitment Status : Recruiting
First Posted : June 23, 2020
Last Update Posted : June 30, 2020
|Condition or disease||Intervention/treatment||Phase|
|COVID-19||Drug: Mesenchymal stem cells Other: Placebo||Phase 2|
All patients will receive 2x10^6 cells/kg on days 1 and day 7 (if needed). The study will be divided in 2 phases. In the first phase, 10 patients will be included and randomized to 2 groups (5 Treatment arm; 5 Control Arm) and receive 2 x10^6 cells/kg MSCs on days 1 and 7 in addition to standard care. Thereafter, the trial committee will meet and evaluate all collected safety and efficacy information to decide about crossover of Control arm to treatment arm if patient deteriorates clinically while in Control arm. Then, 10 new subjects will be included in the study and treated according to protocol.
Preparation of MSCs doses MSCs will be isolated from bone marrow harvested cells. About 50ml bone marrow will be collected from iliac crest using aseptic technique in syringes primed with anticoagulant. The collected sample will be diluted with Phosphate Buffer Saline (PBS) and MSCs will be separated using density gradient centrifugation. After resuspension the cells will be seeded at a fixed concentration of 100,000 cells/cm2 in specially designed flasks and incubated at 37oC in 5% carbondioxide (CO2). Medium will be changed after every third day till harvesting of MSCs from the flasks. Once confluent (approximately day 20) the cells will be harvested with sterile techniques using Trypsin- Ethylenediaminetetraacetic acid ( EDTA ) solution. The prepared cells can either be stored in 50ml cryogenic vials for future use or infused immediately.
Patient Selection and MSCs demand Patient for MSCs and Control arm will be selected by multidisciplinary team (MDT) comprising Critical Care Specialist, Pulmonologist, Infectious Disease Specialist, Clinical Hematologist.
- Demand for MSCs will be initiated on pre-designated forms , signed by Critical care Specialist Clearly indicating indication of MSCs.
- Request form will be sent Stem Cell Lab.
- Incharge stem Cell Lab will authorize issuance of the MSCs dose.
- Stem Cell Lab will issue the dose Administration of MSCs
1. Experimental arm: Frozen MSCs will be resuspended in 100ml normal saline for immediate use and given intravenously. The patients should be pre-medicated to avoid allergic reactions to third party MSCs. Each patient in Experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care 2. Control Arm: Will be Continued on supportive care
Because of the very limited availability of MSCs, their usage has to be rationalized by MDT comprising of pulmonologist, critical care specialist and clinical haematologist and Infectious disease specialist.There is not enough evidence to put forth therapeutic recommendations however, treatment decisions can be made on case to case basis after MDT.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prospective, Randomized Phase 2 Clinical Trial of Mesenchymal Stem Cells(MSCs) for the Treatment of Coronavirus Disease 2019(COVID-19)|
|Actual Study Start Date :||May 1, 2020|
|Estimated Primary Completion Date :||August 30, 2020|
|Estimated Study Completion Date :||September 30, 2020|
Experimental: Mesenchymal stem cells
10 patients will be given mesenchymal stem cells at dose 2x10^6 cells/kg MSCs on days 1 and day 7 (if needed) in addition to standard care
Drug: Mesenchymal stem cells
1. Frozen MSCs will be resuspended in 100ml normal saline for immediate use and given intravenously. The patients should be pre-medicated to avoid allergic reactions to third party MSCs. Each patient in Experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care
Other Name: MSCs
Placebo Comparator: Placebo
Only supportive care will be given to 10 patients
100 ml of normal saline will be given intravenously to control arm
- Overall survival [ Time Frame: 30 days post intervention ]Assessment of Overall survival at 30 days post intervention
- Clinical improvement [ Time Frame: 30 days ]days required for oxygen support independence after intervention
- Time of COVID19 PCR negativity [ Time Frame: day 1,3,7,10, 14 ]PCR testing to check PCR negativity
- Radiological improvement (day 15 and day 30 assessment) [ Time Frame: day 15 and day30 ]Computed tomography Chest assesment will be done to assess improvment in radiological findings of COVID-19
- days required to discharge from hospital [ Time Frame: 30 days post admission ]number of days required for discharge from hospital
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04444271
|Contact: xanab email@example.com|
|Rawalpindi, Punjab, Pakistan, 46000|
|Contact: Xanab Akram 03325346564|
|Study Chair:||xanab akram||NIBMT|